433 Nasal Anti-CD3 Therapy Expands Regulatory T Cells and Improves Motor Recovery After Spinal Cord Injury

View at publisher Summarise with VIRAT
Authors: Joshua I. Chalif, Taha Yahya, Saef Izzy, Yi Lu, Maryam Hazim Al Mansi, Harm Tjebbe Imkamp
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

INTRODUCTION: Spinal cord injury (SCI) triggers a robust inflammatory response that contributes to secondary damage and long-term neurological deficits. Regulatory T cells (Tregs) have shown therapeutic promise in modulating neuroinflammation in central nervous system injury models. However, their role in SCI remains poorly defined. METHODS: Adult C57BL/6J mice underwent moderate contusion SCI at the T8 level. Nasal anti-CD3 monoclonal antibody (1 µg/mouse) was administered beginning 4–6 hours post-injury, daily for 7 days and then three times weekly through day 35. Motor outcomes were assessed using the Basso Mouse Scale and rotarod testing. Inflammatory markers were quantified using RT-qPCR. Flow cytometry and immunofluorescence were used to evaluate Treg expansion and CD3+ cell infiltration. Microglial activation was assessed with Iba-1 staining. RESULTS: Nasal anti-CD3 significantly improved motor function as measured by BMS and rotarod performance, with effects evident by day 7 and sustained through day 35. Treatment increased CD4+ IL-10+ Treg populations in cervical lymph nodes and reduced spinal microglial activation. Spinal cord tissue from treated animals showed reduced expression of pro-inflammatory cytokines (Il1b, Il6, Il17a) and elevated Il10 and Tgfb1 expression. Immunostaining demonstrated increased CD3+ cell infiltration at the injury site, in close association with microglia. CONCLUSIONS: Nasal anti-CD3 therapy expands IL-10-secreting Tregs, dampens neuroinflammation, and improves motor outcomes following SCI. This noninvasive, immune-modulating approach represents a promising therapeutic strategy for addressing the unmet clinical need in spinal cord injury.

Fields of Study & Subjects

Spinal Cord Injury Research Multiple Sclerosis Research Studies T-cell and B-cell Immunology

Publication details

Journal / source
Neurosurgery
Volume
72
Issue
Supplement_1
Pages
124–124
Publication date
26 March 2026
Language
EN